Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Bonti

Bonti
2015 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
$285M LATEST DEAL AMOUNT
Description

Developer of a neurotoxin designed for therapeutic and aesthetic indications for patients with unmet needs. The company develops botulinum neurotoxin for the treatment of muscle hyperactivity, the root cause of musculoskeletal pain in both post-surgical and non-surgical settings, enabling patients to have a long-acting, non-opioid local muscle relaxant without the side effects of currently marketed products.

Website
Formerly Known As
Endurance Biotech
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Primary Office
  • 4921 Birch Street
  • Suite 120
  • Newport Beach, CA 92660
  • United States

+1 (949) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Bonti’s full profile, request a free trial.

Bonti Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 24-Oct-2018 $285M 000.00 00000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 23-Jan-2018 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 18-Apr-2017 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
2. Debt - General 01-Dec-2015 $2M $10.9M Completed Startup
1. Early Stage VC (Series A) 28-Aug-2015 $8.9M $8.9M 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Bonti Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 0,000,000 00.000000 00 00 00 00 00 00.000
Series B 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 7,451,478 $0.000100 8% $1.2 $1.2 1x $1.2 21.14%
To view this company’s complete Cap Table, request access »

Bonti Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genentech Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
0000000 Formerly VC-backed Austin, TX 0 000.00 000000 - 000 000.00
0000 0000000000000 Venture Capital-Backed San Diego, CA 00 00.000 00000000000 00.000
000000000 00000000 Venture Capital-Backed San Carlos, CA 000.00 0000000000 0 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
To view this company’s complete list of competitors, request access »

Bonti Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
City Hill Ventures Venture Capital Minority 000 0000 000000 0
Colt Ventures Venture Capital Minority 000 0000 000000 0
Highlight Capital Venture Capital Minority 000 0000 000000 0
Hunt Technology Ventures Other Minority 000 0000 000000 0
JMCR Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Bonti Executive Team (7)

Name Title Board
Seat
Contact
Info
Fauad Hasan Co-Founder, President, Chief Executive Officer & Board Member
David Ramsay Co-Founder, Chief Financial Officer & Board Member
Wajdie Ahmad Chief Operating Officer & Co-Founder
Mike Jarpe Ph.D Executive Vice President of Drug Development & Co-Founder
Susan Abushakra MD Chief Medical Officer & Co-Founder
You’re viewing 5 of 7 executives. Get the full list »

Bonti Board Members (8)

Name Representing Role Since Contact
Info
David Ramsay Bonti Co-Founder, Chief Financial Officer & Board Member 000 0000
Dennis Huang Bonti Board Member 000 0000
Fauad Hasan Bonti Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Jacob Chacko MD Self Board Member 000 0000
Leonard Brandt Bonti Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 8 board members. Get the full list »